Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 24 for “"Orphan Drugs"”.

  1. Patent Rights & International Public Health: Orphan Drugs

    … of research and investment into less common orphan diseases, resulted in a situation commonly referred to as orphan drugs: drugs targeting those diseases which have not yet been adopted by the pharmaceutical industry. Two main pieces of orphan drug legislation were introduced in the US and …

    nus Repository record for Patent Rights & International Public Health: Orphan Drugs (opens in a new tab) Download file for Patent Rights & International Public Health: Orphan Drugs (opens in a new tab)

  2. Orphan Drugs: Designations, Approvals, and Prices in the US

    … dissertation assessed the characteristics of orphan drug designations and approvals and the factors associated with the time lag between orphan designation and approval in the US from 1983 to 2021. It also evaluated the treatment cost of orphan and non-orphan drugs and factors explaining the …

    chapman Repository record for Orphan Drugs: Designations, Approvals, and Prices in the US (opens in a new tab)

  3. Value Assessment of Orphan Drugs and Treatments for Rare Diseases

    OBJECTIVES: In 1983 the US Orphan Drug Act was passed to facilitate commercialization of drugs to treat rare diseases. The market value for orphan drugs in the US reached $90 billion annually in 2014, with worldwide sales forecast at $176 billion. Payers and policymakers need robust methodology for …

    washington Repository record for Value Assessment of Orphan Drugs and Treatments for Rare Diseases (opens in a new tab)

  4. UTILIZATION CONTROLS FOR ORPHAN DRUGS: PRIOR AUTHORIZATION DOES NOT CORRELATE WITH LOWER DRUG USE

    Background: While 7 of the top selling drugs in the U.S. have orphan status, 95% of 7000 rare diseases still lack treatments. With the growing number of expensive orphan drugs in the market, insurers have increasingly placed utilization controls (UCs), like prior authorization (PA), on orphan drugs …

    jhu Repository record for UTILIZATION CONTROLS FOR ORPHAN DRUGS: PRIOR AUTHORIZATION DOES NOT CORRELATE WITH LOWER DRUG USE (opens in a new tab)

  5. Policies and Price Controls on the Research and Development of Orphan Drugs in the United States and the European Union

    … aims to quantify the differences in US and EU orphan drug development. Orphan drugs are pharmaceutical products that treat rare diseases. Both the EU and US aim to stimulate orphan drug production with policies including national grants, tax credits, and extended periods of market exclusivity. …

    calpoly Repository record for Policies and Price Controls on the Research and Development of Orphan Drugs in the United States and the European Union (opens in a new tab)

  6. Economic Aspects of Reimbursement of Drugs for Rare Diseases

    The reimbursement of drugs that treat rare diseases, also known as orphan drugs, have been the topic of much debate in the last few years presenting a problem to decision makers who are challenged by increasing drug budgets. This thesis covers three main objectives: 1. Are the Incremental Cost …

    toronto-retro Repository record for Economic Aspects of Reimbursement of Drugs for Rare Diseases (opens in a new tab)

  7. Ethics in the service of the rare disease patient: Application of the thought of John Rawls and Paul Ramsey toward the increased availability of orphan drugs

    … is a very small commercial market. Further, drugs for rare diseases are scrutinized by the Food and Drug Administration in the same manner as those for more common diseases--a contingency which, due to the enormous cost of drug research, further discourages profit-driven pharmaceutical …

    rice Repository record for Ethics in the service of the rare disease patient: Application of the thought of John Rawls and Paul Ramsey toward the increased availability of orphan drugs (opens in a new tab)

  8. Issues, Challenges and Opportunities for Economic Evaluation in Rare Diseases

    Background and objectives Orphan drugs have surged in recent decades, but economic evaluation in rare diseases remains challenging. The main research aim set out to explore issues, challenges and opportunities for economic evaluation in rare disease. Methods A comprehensive umbrella review was …

    whiterose Download PDF for Issues, Challenges and Opportunities for Economic Evaluation in Rare Diseases (opens in a new tab)

  9. Expensive drugs for rare diseases : an anthropological analysis of the cultural, political, and economic dimensions of metabolic disease

    … potentially life-saving and/or life lengthening orphan drugs costing anywhere from $100,000.00 to $850,000.00 per patient per year is a complicated matter. This study is an anthropological examination of the debates surrounding ‘expensive drugs for rare diseases’, a term that has come to …

    ubc Repository record for Expensive drugs for rare diseases : an anthropological analysis of the cultural, political, and economic dimensions of metabolic disease (opens in a new tab) Download PDF for Expensive drugs for rare diseases : an anthropological analysis of the cultural, political, and economic dimensions of metabolic disease (opens in a new tab)

  10. Addressing the Needs of Patients with Rare Diseases in Canada: An Evaluation of Orphan Drug Incentives

    … is currently uncertain whether or not a Canadian orphan drug policy will be given further consideration any time in the near future, this thesis seeks to consider the potential impact that three different orphan drug incentives could be expected to have in Canada. Specifically, market exclusivity, …

    sask Repository record for Addressing the Needs of Patients with Rare Diseases in Canada: An Evaluation of Orphan Drug Incentives (opens in a new tab)

  11. Towards accessibility for Rare Diseases RD(s) therapies from an international to local perspective

    … worldwide, yet fewer than 10% have access to orphan drugs (ODs). Variation in how RDs and ODs are defined across countries affects clinical recognition, policy development, research priorities, and access to treatment. In Saudi Arabia (SA), health system transformation under Vision 2030 has …

    qu-belfast Repository record for Towards accessibility for Rare Diseases RD(s) therapies from an international to local perspective (opens in a new tab) Download PDF for Towards accessibility for Rare Diseases RD(s) therapies from an international to local perspective (opens in a new tab)

  12. Custom affinity chromatography : development of a novel platform for rapid creation and validation of affinity media using DNA aptamer based ligands

    … and operations needed to manufacture biologic drugs safely for the treatment of major diseases. Those technologies have enabled development of highly efficient and cost-effective platforms for downstream processing of monoclonal antibody (mAb) based drugs. But translating those advances to …

    ubc Repository record for Custom affinity chromatography : development of a novel platform for rapid creation and validation of affinity media using DNA aptamer based ligands (opens in a new tab) Download PDF for Custom affinity chromatography : development of a novel platform for rapid creation and validation of affinity media using DNA aptamer based ligands (opens in a new tab)

  13. Maximising e-health initiatives to support the diagnosis and tracking of rare diseases

    … Lastly, the thesis assesses the accessibility of orphan drugs, analyses regulatory challenges, and advocates for continued efforts to ensure patients receive necessary treatments. Collectively, these findings advocate for a unified strategy to address the complexities of rare diseases, leveraging …

    qu-belfast Repository record for Maximising e-health initiatives to support the diagnosis and tracking of rare diseases (opens in a new tab) Embargoed until 2029-12-31

  14. Suffering individuals and the sustainable collective : rare disease drug access and care in Canada

    … and manage meaning around controversial costly ‘orphan’ drugs for rare genetic disease in Canada. Based on 18 months of multi-sited ethnographic fieldwork across Canada, I argue that practices around rare disease drug development and access have created two competing moral/ontological frames. …

    ubc Repository record for Suffering individuals and the sustainable collective : rare disease drug access and care in Canada (opens in a new tab) Download PDF for Suffering individuals and the sustainable collective : rare disease drug access and care in Canada (opens in a new tab)

  15. Making the most of a few small population clinical trials

    … by a randomized controlled trial. According to Orphanet, more than 1829 trials among 29 countries focus on more than 800 rare conditions. This number of historical and ongoing trials explains the urgent need for evaluating and developing tailor-made statistical methods for small populations and …

    greece Repository record for Making the most of a few small population clinical trials (opens in a new tab)

  16. MOLECULAR DYNAMICS AND CHEMINFORMATICS METHODS TO EXPLORE THE CHEMICAL REALITY

    … in particular in the evaluation process for orphan drugs (i.e., drugs for rare diseases). A new molecule needs to be dissimilar from any other existing drug for a given disease to be assigned the financially advantageous status of orphan drug. Currently, there are many ways to define whether …

    milano Repository record for MOLECULAR DYNAMICS AND CHEMINFORMATICS METHODS TO EXPLORE THE CHEMICAL REALITY (opens in a new tab)

  17. Development and Licensing of Bio-Pharmaceuticals

    … impact of the United States (US) government's orphan drug incentive scheme on pharmaceutical drug development. Biopharmaceuticals approved in the US and the EU over the last 10 years were searched within publicly accessible sources. These searches identified 147 biopharmaceuticals that were …

    aston Repository record for Development and Licensing of Bio-Pharmaceuticals (opens in a new tab) Download PDF for Development and Licensing of Bio-Pharmaceuticals (opens in a new tab)

Page 1 of 2